Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Benha University
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06993194CT.gov Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury | — | Not Yet Recruiting | — | — | — |
NCT05197439CT.gov Dexmedetomidine Prevents Postoperative Delirium After Deep Brain Stimulation in Patients With Parkinson's Disease | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Delirium
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexmedetomidine (this asset) | Benha University | N/A | D · 30 |
| Propofol | RenJi Hospital | P4 | BB |
| Isoflurane | Duke University | P4 | BB |
| Amantadine | Methodist Rehabilitation Center | P4 | BB |
| Cyclopofol | RenJi Hospital | P4 | BB |
| .Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio- | Konkuk University Medical Center | P4 | BB |
| Pyridostigmine | Konkuk University Medical Center | P4 | BB |
| Suvorexant | Mayo Clinic | P4 | BB |
| Clonidine | Insel Gruppe AG, University Hospital Bern | P4 | BB |
+14 more in the Delirium cohort
Other indications for Dexmedetomidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophreniform Disorder | — | P4 | A · 80 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
| Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexmedetomidine in Delirium. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexmedetomidine-delirium-73149
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →